Literature DB >> 1332211

The procoagulant response of cytomegalovirus infected endothelial cells.

M C van Dam-Mieras1, A D Muller, V W van Hinsbergh, W J Mullers, P H Bomans, C A Bruggeman.   

Abstract

The report describes the effect of an in vitro infection of human umbilical vein endothelial cells with human Cytomegalovirus (CMV). The parameters studied are cellular procoagulant activity, secretion of plasminogen activator inhibitor (PAI-1) and urokinase-type plasminogen activator (u-PA), activation and internalization of factor X and Merocyanine 540 staining. The infection does not result in an increase in PAI-1 and u-PA secretion, but it brings about a procoagulant response, which is relatively rapid compared to the tissue factor mediated response induced by inflammatory mediators. The time course and the coagulation factor dependency suggest a facilitated interaction of coagulation factors on the surface of infected cells. Chromogenic activity measurements after the addition of purified factor X and electron microscopic examination of the cells after addition of colloidal gold-factor X conjugates both point to an internalization of factor X and/or Xa after interaction with the endothelial cell surface. Merocyanine 540 staining suggests that CMV infection leads to membrane perturbations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332211

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  A sensitive method for quantifying cytomegalic endothelial cells in peripheral blood from cytomegalovirus-infected patients.

Authors:  A M Kas-Deelen; M C Harmsen; E F de Maar; W J van Son; T H The
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

3.  Coagulation initiated on herpesviruses.

Authors:  M R Sutherland; C M Raynor; H Leenknegt; J F Wright; E L Pryzdial
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 4.  Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination.

Authors:  David G Meyers
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

5.  Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease.

Authors:  Akifumi Kuwabara; Haruhiko Okamoto; Takeyasu Suda; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

Review 6.  [Cytomegalovirus and herpes simplex virus in pathogenesis and progression of native arteriosclerosis and recurrent stenosis after intervention].

Authors:  M Herzum; J R Schaefer; G Hufnagel; B Maisch
Journal:  Herz       Date:  1998-05       Impact factor: 1.443

7.  Infectious burden and carotid plaque thickness: the northern Manhattan study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Yeseon Park Moon; Bernadette Boden-Albala; Khin M Liu; Steven Spitalnik; Tanja Rundek; Ralph L Sacco; Myunghee C Paik
Journal:  Stroke       Date:  2010-01-14       Impact factor: 7.914

8.  Enhanced cytomegalovirus infection in atherosclerotic human blood vessels.

Authors:  Pamela L Nerheim; Jeffery L Meier; Mohammad A Vasef; Wei-Gen Li; Ling Hu; James B Rice; Daniel Gavrila; Wayne E Richenbacher; Neal L Weintraub
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

9.  Pulmonary embolism and portal vein thrombosis in an immunocompetent adolescent with acute cytomegalovirus hepatitis.

Authors:  Antonio Mendoza Ladd; Rakesh Goyal; Louis Rosainz; Peter Baiocco; Larry DiFabrizio
Journal:  J Thromb Thrombolysis       Date:  2008-12-31       Impact factor: 2.300

10.  Membrane related effects in endothelial cells induced by human cytomegalovirus.

Authors:  A G van Geelen; M E Slobbe-van Drunen; A D Muller; C A Bruggeman; M C Van Dam-Mieras
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.